MX2008002179A - Anticuerpos anti-il-23. - Google Patents

Anticuerpos anti-il-23.

Info

Publication number
MX2008002179A
MX2008002179A MX2008002179A MX2008002179A MX2008002179A MX 2008002179 A MX2008002179 A MX 2008002179A MX 2008002179 A MX2008002179 A MX 2008002179A MX 2008002179 A MX2008002179 A MX 2008002179A MX 2008002179 A MX2008002179 A MX 2008002179A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
binding portions
subunit
treatment
Prior art date
Application number
MX2008002179A
Other languages
English (en)
Inventor
Craig Duane Dickinson
Alain Philippe Vasserot
David Matthew Marquis
Kristine Kay Kikly
Catherine Brautigam Beidler
Stuart Willis Bright
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2008002179A publication Critical patent/MX2008002179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion abarca anticuerpos aislados, o porciones del mismo enlazantes al antigeno, que se enlazan especificamente a la subunidad p19 de IL-23. Estos anticuerpos, o porciones del mismo enlazantes al antigeno, tienen anticuerpos neutralizantes de alta afinidad, utiles para el tratamiento de enfermedades autoinmunes.
MX2008002179A 2005-08-25 2006-08-23 Anticuerpos anti-il-23. MX2008002179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71133605P 2005-08-25 2005-08-25
US77235506P 2006-02-10 2006-02-10
PCT/US2006/032752 WO2007024846A2 (en) 2005-08-25 2006-08-23 Anit-il-23 antibiodies

Publications (1)

Publication Number Publication Date
MX2008002179A true MX2008002179A (es) 2008-04-22

Family

ID=37616511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002179A MX2008002179A (es) 2005-08-25 2006-08-23 Anticuerpos anti-il-23.

Country Status (21)

Country Link
US (1) US7872102B2 (es)
EP (1) EP1937721B1 (es)
JP (1) JP5022367B2 (es)
KR (1) KR101028200B1 (es)
AT (1) ATE475672T1 (es)
AU (1) AU2006283194B9 (es)
BR (1) BRPI0615018A2 (es)
CA (1) CA2619052A1 (es)
CY (1) CY1110792T1 (es)
DE (1) DE602006015830D1 (es)
DK (1) DK1937721T3 (es)
EA (1) EA013506B1 (es)
ES (1) ES2347690T3 (es)
HK (1) HK1119712A1 (es)
IL (1) IL188312A0 (es)
MX (1) MX2008002179A (es)
NO (1) NO20081465L (es)
PL (1) PL1937721T3 (es)
PT (1) PT1937721E (es)
SI (1) SI1937721T1 (es)
WO (1) WO2007024846A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
PL1931710T3 (pl) * 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
SI2187964T1 (sl) * 2007-08-10 2015-01-30 Regeneron Pharmaceuticals, Inc. Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
SG172275A1 (en) 2008-12-19 2011-07-28 Schering Corp Feed supplement for mammalian cell culture and methods of use
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2435480A1 (en) * 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
WO2011011797A2 (en) * 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP3456740A1 (en) * 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
EP4039275A1 (en) * 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
NZ712294A (en) 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
EP3689369A1 (en) 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
SG11201701423RA (en) 2014-09-03 2017-03-30 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP2018512422A (ja) 2015-04-14 2018-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 疾患の処置法
KR20180063127A (ko) 2015-09-17 2018-06-11 암젠 인크 Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
CN108472367A (zh) 2015-12-22 2018-08-31 美国安进公司 作为对il23拮抗剂的临床应答的预测因子的ccl20
EP3560956A3 (en) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
EP3848390A1 (en) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
AU2019300491A1 (en) 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN114773466B (zh) * 2020-11-26 2023-08-29 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045480B2 (ja) * 1996-12-20 2000-05-29 大同メタル工業株式会社 ボーリング盤
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
ES2300276T5 (es) * 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
PL1601694T3 (pl) * 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
JP4903061B2 (ja) * 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
EP1971366B1 (en) * 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
RU2435435C2 (ru) * 2007-02-22 2011-12-10 Хилл'c Пет Ньютришн, Инк. Композиция и способ улучшения развития растущих животных

Also Published As

Publication number Publication date
DE602006015830D1 (de) 2010-09-09
AU2006283194B9 (en) 2011-02-03
BRPI0615018A2 (pt) 2011-04-26
IL188312A0 (en) 2008-04-13
DK1937721T3 (da) 2010-10-18
SI1937721T1 (sl) 2010-11-30
CA2619052A1 (en) 2007-03-01
NO20081465L (no) 2008-05-15
WO2007024846A3 (en) 2007-06-07
EP1937721B1 (en) 2010-07-28
ATE475672T1 (de) 2010-08-15
HK1119712A1 (en) 2009-03-13
JP2009506041A (ja) 2009-02-12
WO2007024846A2 (en) 2007-03-01
PT1937721E (pt) 2010-09-17
EA200800417A1 (ru) 2008-06-30
CY1110792T1 (el) 2015-06-10
ES2347690T3 (es) 2010-11-03
US7872102B2 (en) 2011-01-18
KR20080031450A (ko) 2008-04-08
AU2006283194B2 (en) 2010-10-21
EA013506B1 (ru) 2010-06-30
US20090240036A1 (en) 2009-09-24
KR101028200B1 (ko) 2011-04-11
AU2006283194A1 (en) 2007-03-01
PL1937721T3 (pl) 2010-12-31
EP1937721A2 (en) 2008-07-02
AU2006283194B8 (en) 2010-10-28
JP5022367B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
IL188312A0 (en) Anti-il-23 antibodies
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA200870050A1 (ru) Анти-il-17-антитела
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
UA92505C2 (ru) Композиции на основе антитела против cd3
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
TW200740844A (en) Novel MAdCAM antibodies
MX2009006891A (es) Anticuerpos cd44.
TW200626171A (en) Fixed dosing of HER antibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
NO20084878L (no) Humanisert C-kit antistoff
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
MY156315A (en) Anti-vegf antibodies
WO2009026117A3 (en) Novel compounds
WO2009112245A9 (en) Antibody against the csf-1 r
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
WO2011004028A3 (en) Tlr3 binding agents
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration